Global Tobacco Giants Push Nicotine Pouches After FDA Authorizes Reduced-Risk Claims

| Input:

While BAT and Philip Morris champion oral nicotine as a primary growth engine, South Korea's weight-based tax structure and regulatory blind spots complicate a domestic rollout

Placed orally between the lip and gum to deliver nicotine without smoke, nicotine pouches are gaining rapid global popularity as a reduced-risk alternative to traditional cigarettes. However, a domestic expansion into South Korea faces significant obstacles, including heavy weight-based tax burdens that complicate product pricing and ongoing concerns over regulatory blind spots. Photo=Getty Image Bank
Placed orally between the lip and gum to deliver nicotine without smoke, nicotine pouches are gaining rapid global popularity as a reduced-risk alternative to traditional cigarettes. However, a domestic expansion into South Korea faces significant obstacles, including heavy weight-based tax burdens that complicate product pricing and ongoing concerns over regulatory blind spots. Photo=Getty Image Bank

Multinational tobacco corporations dominating the global market are rapidly shifting focus toward non-combustible alternatives.

British American Tobacco (BAT), the U.K.-based manufacturer behind Dunhill, announced at an investor conference on September 30 that it will position new product categories—specifically oral nicotine pouches—as its core growth engine moving forward.

Industry analysts attribute BAT’s strategic pivot to declining sales of traditional combustible cigarettes. BAT’s internal portfolio projections indicate that the oral nicotine sector, which includes nicotine gum and pouches administered orally, will grow at an average annual rate of 23%. If realized, the global oral nicotine market is expected to reach 11 billion pounds (approximately 19.82 trillion won) by 2030. In the first half of this year, BAT’s oral nicotine division posted a 65.9% year-over-year sales increase, comfortably outpacing forecasts.

Despite the shift, BAT is not abandoning traditional cigarettes immediately. "We will maintain our core businesses in cigarettes and e-cigarettes while executing a strategy to secure multiple forms of nicotine consumption," BAT Group CEO Tadeu Marroco told investors.

Philip Morris International (PMI) outlined a similar trajectory during its investor briefing in May. While combustible cigarettes accounted for roughly 81% of PMI’s total sales volume in 2025, cigarette sales fell by an average of 2% annually from 2022 to 2025. In contrast, nicotine pouches—which comprised just over 1% of total volume in 2025—achieved an average annual growth rate of 54% over the same period, making them the fastest-growing segment in the tobacco industry.

FDA Approval Sparks Global Health Debate

Nicotine pouches consist of solid, pharmaceutical-grade nicotine and plant fibers packed into small cotton pouches resembling tea bags, which users place between their lip and gum. Because they require no combustion or inhalation, they produce no smoke or vapor, driving rapid adoption across Europe and the United States.

Market research firm Euromonitor reports that nicotine pouches accounted for 2.6% of the global tobacco market in 2024. A study by University of Southern California researchers estimated that 5.4% of U.S. smokers utilized nicotine pouches that same year.

While initially viewed as a niche alternative, the market momentum shifted dramatically on June 30 when the U.S. Food and Drug Administration (FDA) authorized PMI’s ZYN brand to utilize specific reduced-risk language on product packaging. The FDA permitted claims stating that completely switching from cigarettes to ZYN lowers the risk of oral cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.

The ruling drew immediate backlash from public health advocacy groups. The American Cancer Society Cancer Action Network criticized the decision, arguing that regulatory authorities were effectively endorsing marketing campaigns for major tobacco companies. Conversely, proponents argue that eliminating tar and carbon monoxide exposure makes pouches a significantly safer harm-reduction tool compared to combustible cigarettes.

Medical experts, however, warn that nicotine pouches carry distinct health risks. Unfiltered mucosal absorption of high-concentration nicotine can accelerate cardiovascular strain and intensify chemical dependence. Direct, prolonged contact with oral tissues also heightens the risk of localized oral conditions, including stomatitis and periodontitis.

Tax Barriers and Regulatory Blind Spots in South Korea

Despite rapid global growth, major tobacco manufacturers have stalled commercial launches of nicotine pouches in South Korea. Overseas flagship lines—such as PMI’s ZYN and BAT’s Velo—have yet to finalize domestic distribution timelines. Similarly, while South Korean tobacco leader KT&G acquired a controlling stake in Nordic pouch manufacturer ASF last year, it has not introduced an oral pouch product domestically.

Industry executives identify South Korea's rigid tax structure as the primary barrier to entry. Under current tax statutes, combustible cigarettes are taxed per stick, while liquid e-cigarettes are taxed per milliliter. Nicotine pouches, classified as chewing tobacco, are taxed by weight (grams).

Chewing tobacco incurs a tobacco consumption tax of 364 won per gram, an individual consumption tax of 325 won per gram, and a National Health Promotion Fund charge of 534.5 won per gram. When combined with local education taxes and value-added tax (VAT), the tax burden exceeds 1,200 won per gram. Consequently, a standard 10-gram tin incurs over 10,000 won in statutory taxes alone before factoring in production, import, or retail margins. Unlike the U.S. or the European Union, which apply lower tax rates to non-combustible products based on harm-reduction principles, South Korea's weight-based taxation renders commercial pricing unviable.

Beyond tax hurdles, public health experts express concern over prospective regulatory enforcement once nicotine pouches enter the market.

Although South Korea revised the Tobacco Business Act on April 24 to expand the legal definition of tobacco to include synthetic nicotine products, enforcement mechanisms remain ill-suited for oral pouches. Because pouches are odorless and invisible during use, enforcing bans in designated non-smoking public areas is practically impossible. Educational institutions in the U.S. and the U.K. have already reported widespread illicit student use during classroom instruction.

In addition, critics warn that in South Korea—where public awareness of chewing tobacco remains low—manufacturers could market nicotine pouches as unauthorized smoking-cessation aids.

"Structurally, nicotine pouches function similarly to nicotine gum or patches, delivering nicotine directly into the body to avoid the harmful substances produced when burning cigarettes," an industry official told Comedydotcom in a phone interview on October 2. "There is a strong possibility we will see a repeat of past trends, where liquid e-cigarettes used a similar approach and were marketed as smoking-cessation tools."

According to the official, after synthetic-nicotine liquid e-cigarettes were brought under the legal definition of tobacco, manufacturers responded by releasing nicotine-free products or variants using nicotine analogues not covered by the revised Tobacco Business Act. Many of these newly repositioned products allow teenagers to access sales information and product reviews on major portal sites without adult verification.

"There is no guarantee that this kind of exploitation of regulatory blind spots will not reappear with nicotine pouches," the official said. "It is time for a regulatory policy that broadly covers all tobacco alternatives."

×